Becton Dickinson and Co to Post FY2019 Earnings of $11.67 Per Share, Jefferies Financial Group Forecasts (NYSE:BDX)

Becton Dickinson and Co (NYSE:BDX) – Equities research analysts at Jefferies Financial Group decreased their FY2019 earnings estimates for Becton Dickinson and in a research note issued on Tuesday, May 21st, according to Zacks Investment Research. Jefferies Financial Group analyst B. Couillard now forecasts that the medical instruments supplier will earn $11.67 per share for the year, down from their previous forecast of $12.10. Jefferies Financial Group also issued estimates for Becton Dickinson and’s Q1 2020 earnings at $2.97 EPS, Q2 2020 earnings at $3.03 EPS, Q3 2020 earnings at $3.25 EPS and Q4 2020 earnings at $3.59 EPS.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.57 by $0.02. The firm had revenue of $4.20 billion during the quarter, compared to analysts’ expectations of $4.25 billion. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The firm’s revenue for the quarter was down .6% compared to the same quarter last year. During the same period last year, the firm posted $2.65 earnings per share.

A number of other research firms have also commented on BDX. ValuEngine lowered shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Monday, April 1st. Zacks Investment Research raised shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a research note on Wednesday, April 10th. Barclays raised their price objective on shares of Becton Dickinson and from $260.00 to $266.00 and gave the stock an “equal weight” rating in a research note on Monday, April 15th. Raymond James decreased their price objective on shares of Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating for the company in a research note on Tuesday, March 19th. Finally, KeyCorp reaffirmed an “overweight” rating and issued a $262.00 price objective (down previously from $273.00) on shares of Becton Dickinson and in a research note on Friday, May 10th. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $255.31.

Becton Dickinson and stock traded down $2.88 during midday trading on Thursday, reaching $234.16. The stock had a trading volume of 984,241 shares, compared to its average volume of 1,268,337. Becton Dickinson and has a twelve month low of $208.62 and a twelve month high of $265.87. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.59 and a current ratio of 0.96. The firm has a market capitalization of $63.79 billion, a price-to-earnings ratio of 21.27, a P/E/G ratio of 1.75 and a beta of 1.12.

The business also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Friday, June 7th will be paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.32%. The ex-dividend date is Thursday, June 6th. Becton Dickinson and’s dividend payout ratio (DPR) is currently 27.97%.

In other Becton Dickinson and news, EVP Simon D. Campion sold 2,903 shares of Becton Dickinson and stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $236.94, for a total transaction of $687,836.82. Following the completion of the sale, the executive vice president now owns 9,408 shares of the company’s stock, valued at approximately $2,229,131.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Betty D. Larson sold 1,700 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $224.97, for a total transaction of $382,449.00. Following the transaction, the executive vice president now owns 11,493 shares in the company, valued at approximately $2,585,580.21. The disclosure for this sale can be found here. Insiders have sold a total of 21,154 shares of company stock valued at $4,955,775 in the last three months. Company insiders own 0.12% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in BDX. Meridian Wealth Advisors LLC raised its holdings in Becton Dickinson and by 2.7% in the 1st quarter. Meridian Wealth Advisors LLC now owns 3,787 shares of the medical instruments supplier’s stock worth $946,000 after acquiring an additional 99 shares during the period. Pratt Collard Advisory Partners LLC raised its holdings in Becton Dickinson and by 5.1% in the 1st quarter. Pratt Collard Advisory Partners LLC now owns 2,078 shares of the medical instruments supplier’s stock worth $519,000 after acquiring an additional 100 shares during the period. Investec Asset Management North America Inc. raised its holdings in Becton Dickinson and by 5.1% in the 1st quarter. Investec Asset Management North America Inc. now owns 11,123 shares of the medical instruments supplier’s stock worth $2,778,000 after acquiring an additional 543 shares during the period. British Airways Pensions Investment Management Ltd raised its holdings in Becton Dickinson and by 10.3% in the 1st quarter. British Airways Pensions Investment Management Ltd now owns 87,805 shares of the medical instruments supplier’s stock worth $21,928,000 after acquiring an additional 8,207 shares during the period. Finally, Orrstown Financial Services Inc. raised its holdings in Becton Dickinson and by 6.5% in the 1st quarter. Orrstown Financial Services Inc. now owns 4,368 shares of the medical instruments supplier’s stock worth $1,091,000 after acquiring an additional 267 shares during the period. Institutional investors and hedge funds own 84.58% of the company’s stock.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: What are economic reports?

Get a free copy of the Zacks research report on Becton Dickinson and (BDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.